Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
P/B ratio for Tiziana Life Sciences Ltd (TLSA)
P/B ratio as of 2023: 0.00
According to Tiziana Life Sciences Ltd's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/B ratio of 3.11.
P/B ratio history for Tiziana Life Sciences Ltd from 1998 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 3.11 |
| 2021 | 2.28 |
| 2020 | 5.48 |
| 2019 | -26.89 |
| 2018 | 285.67 |
| 2017 | -144.57 |
| 2016 | 154.82 |
| 2015 | 41.04 |
| 2014 | 44.30 |
| 2013 | -11455.95 |
| 2012 | -34051.09 |
| 2011 | 2358.56 |
| 2010 | 356.61 |
| 2009 | 71.99 |
| 2008 | 34.70 |
| 2007 | 8.05 |
| 2006 | 533.24 |
| 2005 | 381.99 |
| 2004 | 179.79 |
| 2003 | 173.40 |
| 2002 | 110.14 |
| 2001 | 66.93 |
| 2000 | 44.74 |
| 1999 | 83.00 |
| 1998 | 69.36 |